Skip to content
Open in App
Acumen Pharmaceuticals logo

Acumen Pharmaceuticals

web2

Acumen Pharmaceuticals is a clinical stage biotechnology company developing experimental antibo...

Symbol ยท ABOS
Company profile

About

Acumen Pharmaceuticals is a clinical stage biotechnology company developing experimental antibody treatments for Alzheimer's disease, with research focused on toxic soluble amyloid beta oligomers in the brain. Its principal investigational medicine, sabirnetug, is designed to selectively bind these protein aggregates, which researchers associate with damage to neuronal function. The company is evaluating sabirnetug in the ALTITUDE AD Phase 2 clinical trial involving patients with early Alzheimer's disease. It is also investigating alternative administration methods and developing an Enhanced Brain Delivery program with JCR Pharmaceuticals. These activities concern investigational therapies rather than commercially approved Alzheimer's disease treatments.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ABOS
Expert coverage

Acumen Pharmaceuticals profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment